Key Stats for Merck Stock
- Past-Week Performance: +1.3%
- 52-Week Range: $73.3 to $125.1
- Current Price: $121.4
What Happened?
Merck‘s decision to split its human health business into two units signals a company building its post-Keytruda identity now, with MRK stock trading at $121.41 as investors weigh a pipeline worth $70 billion in non-risk-adjusted opportunity.
On February 23, Merck announced the reorganization into an Oncology Business Unit and a Specialty, Pharma and Infectious Diseases unit, appointing Brian Foard from Sanofi and Jannie Oosthuizen to lead each division, while also laying off 154 employees at its Gardasil manufacturing facility in Durham County on February 27.
The structural urgency becomes undeniable when Keytruda’s $31.7 billion in FY 2025 revenue sits against a compound patent expiring December 2028, yet two Welireg PDUFA dates on June 19 and October 4 already confirm the replacement pipeline is moving through regulators on schedule.
Meanwhile, CEO Robert Davis stated on the Q4 earnings call that “we now have line of sight to over $70 billion of potential commercial opportunity by the mid-2030s,” a claim backed by the April 28 PDUFA date for doravirine/islatravir, Merck’s next potential HIV blockbuster already awaiting FDA action.
With Welireg posting 41% revenue growth to $716 million in FY 2025 and two RCC approvals potentially landing within months, Merck is methodically converting pipeline into revenue before the Keytruda cliff forces the market to finally reprice the stock.
Wall Street’s Take on Merck Stock
Merck’s February 23 reorganization into two human health units directly accelerates its post-Keytruda commercial infrastructure, positioning over 20 pipeline launches to drive revenue growth before the 2028 patent expiry hits.
Fundamentally, Merck grew FY 2025 revenue to $65.0 billion with non-GAAP EPS of $8.98, though 2026 estimates project EPS compressing to $5.12 as the $9 billion Cidara charge weighs on near-term margins.
Wall Street currently shows 15 buys, 4 outperforms, and 11 holds against a mean price target of $127.21, implying 4.8% upside from the March 2 close of $121.41, with conviction holding despite Keytruda LOE anxiety.
The analyst target range spans $100 on the low end to $150 on the high end, where the upside case hinges on Welireg’s dual RCC approvals in June and October and the downside reflects Keytruda biosimilar timing risk.
What Does the Valuation Model Say?
The TIKR valuation model sets a mid-case target of $182.13, implying 50% total return over 4.8 years at an 8.7% annualized IRR from today’s $121.41 price.
The market is pricing Merck as a patent-cliff story, yet the $70 billion non-risk-adjusted pipeline opportunity is more than 2x Keytruda’s consensus 2028 peak revenue of $35 billion.
Welireg alone posted $716 million in FY 2025 sales, up 41%, with two FDA-accepted supplemental applications and PDUFA dates already set for mid and late 2026.
Management’s commitment to $3 billion in share repurchases for 2026 and a raised quarterly dividend of $0.85 per share signals that leadership sees the current price as disconnected from intrinsic value.
However, if Keytruda’s compound patent fails to hold beyond December 2028 and biosimilar erosion accelerates, the $31.7 billion revenue base representing nearly half of total sales faces rapid compression.
The April 28 PDUFA decision on doravirine/islatravir will serve as the first concrete signal of whether Merck’s post-Keytruda pipeline can deliver commercially meaningful approvals on schedule.
MRK is undervalued at $121.41 given a $182.13 mid-case model target, but the thesis fully crystallizes only when pipeline derisking events confirm growth trajectory through 2027.
Should You Invest in Merck & Co, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up MRK stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Merck & Co Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze MRK stock on TIKR for Free →
